Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical Limited announced that its new drug, TQC3302, a triple-combination soft mist inhalation formulation for chronic obstructive pulmonary disease (COPD), has received clinical trial approval from China’s National Medical Products Administration. This development marks a significant step in the company’s efforts to provide advanced treatment options for COPD patients, as no similar formulation has been approved globally, potentially enhancing the company’s market position and offering new opportunities for stakeholders.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.19 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. The company specializes in developing innovative drugs, particularly in the respiratory domain, and is known for its advanced soft mist inhalation technology platform.
Average Trading Volume: 167,116,257
Technical Sentiment Signal: Buy
Current Market Cap: HK$130.9B
Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.